Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06142357
Status:
RECRUITING
Last Update Posted:
2024-04-10
First Post:
2023-11-16
Brief Title:
Secukinumab Drug Survival Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Prospective Observational Study With Retrospective Part to Evaluate Secukinumab Drug Survival Effectiveness and Tolerability in Pediatric Patients With Moderate-to-severe Plaque Psoriasis
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPARROW
Brief Summary:
Multicenter non-interventional cohort study in pediatric patients with moderate to severe plaque-type psoriasis Retrospective data collection is planned at patients inclusion
Detailed Description:
This observational study will be performed at healthcare facilities treating pediatric psoriasis patients The study population will consist of a representative group of pediatric patients with moderate-to-severe plaque psoriasis for whom routine treatment with secukinumab according to the approved national label is initiated during 4 to 16 weeks Retrospective data collection is planned at patients inclusion Prospective data collection will continue during follow-up routine visits until secukinumab discontinuation or maximum duration of follow-up for 104 weeks after index date
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None